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Mucosal-associated invariant T (MAIT) cells are innate T lymphocytes activated by 38 
bacteria that produce vitamin B2 metabolites. Mouse models of infection have 39 
demonstrated a role for MAIT cells in antimicrobial defence. However, proposed 40 
protective roles of MAIT cells in human infections remain unproven and clinical 41 
conditions associated with selective absence of MAIT cells have not been identified. 42 
We report that typhoidal and non-typhoidal Salmonella enterica strains activate MAIT 43 
cells. However, S. Typhimurium sequence type 313 (ST313) lineage 2 strains, which 44 
are responsible for the burden of multidrug-resistant non typhoidal invasive disease in 45 
Africa, escape MAIT cell recognition through overexpression of ribB. This bacterial 46 
gene encodes the 4-dihydroxy-2-butanone-4-phosphate synthase enzyme of the 47 
riboflavin biosynthetic pathway. This MAIT cell-specific phenotype did not extend to 48 
other innate lymphocytes. We propose that ribB overexpression is an evolved trait that 49 
facilitates evasion from immune recognition by MAIT cells and contributes to the 50 
invasive pathogenesis of S. Typhimurium ST313 lineage 2. 51 
 52 
 53 
  54 
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STATEMENT OF SIGNIFICANCE 55 
Non-typhoidal Salmonella serotypes are a common cause of self-limiting 56 
diarrhoeal illnesses in healthy adults. However, recently, a highly invasive multi-drug 57 
resistant Salmonella Typhimurium sequence type 313 has emerged as a major cause 58 
of morbidity and mortality in sub-Saharan Africa, particularly in children and 59 
immunosuppressed individuals. In this paper we describe escape from MAIT cell 60 
recognition as an additional mechanism of immune evasion of S. Typhimurium ST313. 61 
As MAIT cells represent an early defence mechanism against pathogens at mucosal 62 
surfaces, and their frequency and function are altered in immunosuppressed 63 
individuals in sub-Saharan Africa, harnessing their function may offer an important 64 
therapeutic strategy to improve mucosal immunity. 65 
 66 






The Gram-negative bacterium Salmonella enterica spp. comprises many serovars 71 
which are closely related phylogenetically but cause very different disease 72 
presentations and distinct immune responses in immunocompetent hosts [1], [2]. 73 
Infection by the human restricted Salmonella typhoidal serovars (S. Typhi and S. 74 
Paratyphi) results in a severe systemic disease called enteric fever. In contrast, 75 
nontyphoidal serovars originating from zoonotic reservoirs such as S. Typhimurium 76 
and S. Enteritidis, cause self-limiting diarrhoeal disease in healthy individuals [1]–[3]. 77 
Multi-drug resistant S. Typhimurium strains of a distinct multilocus sequence type 313 78 
(ST313) recently emerged in sub-Saharan Africa. S. Typhimurium ST313 is associated 79 
with invasive blood stream infections in immunocompromised individuals and is distinct 80 
from the S. Typhimurium strains that cause gastroenteritis globally.  81 
 82 
Since it was first reported in 2009 [4], the S. Typhimurium ST313 clade has become 83 
the major cause of invasive nontyphoidal Salmonella (iNTS) disease in Africa [5], [6], 84 
and comprises two sub-clade lineages [6], termed lineages 1 and 2. Bacteraemia by 85 
iNTS causes an estimated 77,500 deaths annually worldwide [7], primarily in Africa, 86 
among young children with recent malaria, malarial anaemia or malnutrition and in 87 
adults afflicted with HIV, among whom recurrent disease is also common [1], [5], [8]–88 
[11]. S. Typhimurium ST313 isolates have rarely been reported outside of Africa [4] 89 
and African ST313 blood isolates are genetically distinct from rare diarrhoeal ST313  90 
isolates found in the United Kingdom [12] or Brazil [13]. Genotypic and phenotypic 91 
analyses of several clinical isolates of the two well-described ST313 lineages identified 92 
signatures of metabolic adaptation and unique enteropathogenesis in animal models, 93 
consistent with adaptation to invasive disease in an immunocompromised human 94 
population [4], [14], [15].  95 
 96 
B and T cell responses can mediate a protective role in mouse models of Salmonella 97 
infection. B cells provide the first line of defence at mucosal sites to restrain systemic 98 
dissemination, while T cells are needed for Salmonella clearance [16]–[18]. Cross-99 
reactive and serovar-specific MHC-restricted T cell responses have been well 100 
characterised in humans [19]–[24]. Salmonella can also induce activation of non-MHC-101 
restricted T cells, specifically gd T cells, invariant Natural Killer T cells (iNKT) and 102 
Mucosal-associated invariant T (MAIT) cells [25]–[27], although their protective role 103 




MR1-restricted MAIT cells comprise a highly conserved class of semi invariant T cells, 106 
bridging innate and adaptive immunity [28]. The MHC class I-like molecule MR1, 107 
bound to derivatives of vitamin B2 intermediates, activates MAIT cells [29]. This 108 
process can drive antibacterial activity, in vitro and in vivo, and correlates with the 109 
presence of the vitamin B2 biosynthetic pathway in several commensal and pathogenic 110 
bacteria and fungal species (reviewed in [30]). Similar to iNKT and gd T cells, MAIT 111 
can be activated by cytokines (IL-12, IL-18, type I IFN) independently of their TCR 112 
engagement [31]. The ability of MAIT cells to recognise S. Typhimurium-infected 113 
targets [32] prompted the identification, within bacterial supernatants, of the potent 114 
MAIT cell agonists (lumazine and pyrimidines), derivatives of the vitamin B2 115 
intermediate 5-A-RU [29], [33]. Following intranasal infection with S. Typhimurium, 116 
murine MAIT cells become activated and accumulate in the lungs [26]. Human 117 
challenge studies with typhoidal serovars (S. Typhi and S. Paratyphi A) also 118 
demonstrated sustained MAIT cell activation and proliferation at peak of infection [34], 119 
[35]. 120 
 121 
While many commensal and pathogenic bacteria possess the riboflavin biosynthetic 122 
pathway, the levels of resulting MAIT stimulation varies [36], [37], perhaps reflecting 123 
the influence of microenvironment on bacterial metabolism and antigen availability. 124 
The ability of MAIT cells to recognise and respond to several isolates of the same 125 
pathogen may also vary depending on metabolic differences between isolates [38].  126 
 127 
We hypothesized that MAIT cells contributed to the cellular response to Salmonella 128 
enterica serovars responsible for invasive disease, and examined the ability of MAIT 129 
cells to recognise and respond to different S. enterica serovars associated to invasive 130 
disease in Africa. Here, we demonstrate that S. Typhimurium ST313 lineage 2 isolates 131 
escape MAIT cell recognition through overexpression of RibB, a bacterial enzyme of 132 
the riboflavin biosynthetic pathway. Our results suggest that MAIT cell immune 133 
protection represents an important ‘evolutionary bottleneck’ for the pathogen. 134 
 135 





Identification of cellular responses to multiple Salmonella enterica subsp 139 
enterica serovars.  140 
 141 
To identify potential differences in the response of innate and adaptive T cells to 142 
distinct Salmonella pathovars, we focused on two pathovariants of S. Typhimurium 143 
that are responsible for different types of human disease. S. Typhimurium ST313 is 144 
associated with invasive disease among immunocompromised individuals in Africa 145 
and a representative isolate is D23580 (STM-D23580). S. Typhimurium sequence type 146 
19 (ST19) causes non-invasive diarrhoeal infections in immunocompetent individuals 147 
globally (a representative isolate is LT2, designated STM-LT2). Peripheral blood 148 
mononuclear cells (PBMC) isolated from healthy donors were infected with both 149 
S. Typhimurium pathovariants, and S. Typhi strain Ty2 (ST-Ty2) was used to represent 150 
a more distantly related serovar that causes invasive disease in immunocompetent 151 
individuals. Escherichia coli (E. coli) was included as unrelated control. Upon infection, 152 
PBMC were incubated overnight in the presence of brefeldin A to permit intracellular 153 
cytokine accumulation. T lymphocytes were stained with a panel of fluorescently 154 
labelled antibodies to simultaneously identify different T cell populations (MAIT, gd, 155 
CD4 and CD8), and determine their activation status (CD69) and cytokine production 156 
(IFN-g and TNF-a).  157 
 158 
We first defined the heterogeneity of T cell responses to Salmonella, by performing an 159 
unsupervised clustering analysis on all CD3+ T cells expressing the activation marker 160 
CD69 following overnight incubation with the Salmonella pathovariants. Dimensionality 161 
reduction analysis by t-SNE revealed 22 populations of CD3+ CD69+ T cells, some of 162 
which differed in frequency according to the infecting Salmonella pathogen. Clusters 163 
were then annotated and assigned to MAIT (identified as CD3+ Va7.2+ CD161high), gd+, 164 
CD4+ or CD8+ T cell subsets based on the expression of distinct phenotypic markers.  165 
 166 
We discovered that a group of clusters of MAIT cells (clusters 6, 15, 18, 21) was under-167 
represented among all CD69+ cells upon infection with STM-D23580, compared with 168 
STM-LT2, ST-Ty2 and E. coli (Figure 1A). Next, we analysed expression of IFN-g and 169 
TNF-a in CD69+ activated T cells. We determined that the under-represented clusters 170 
of CD69+ MAIT cells represented IFN-g and TNF-a producing MAIT cells (Figure 1B).   171 
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MAIT cells were next analysed using Uniform Manifold Approximation and Projection 172 
(UMAP), a neighbouring dimensionality reduction technique that preserves embedding 173 
and global distances better than t-SNE [39], and clearly defined the trajectory of the 174 
distinct subpopulations of Salmonella-activated MAIT cells (Figure 1C). STM-LT2 175 
stimulated MAIT cells clustered close to MAIT cells stimulated with ST-Ty2 and E. coli, 176 
which were characterised by elevated expression of CD69 and the presence of  single 177 
and double producers of TNF-a and IFN-g. In contrast, STM-D23580 stimulated MAIT 178 
cells clustered closer to unstimulated cells, away from MAIT cells stimulated with ST-179 
Ty2 and E. coli (Figure 1D, top left panel). STM-D23580 stimulated MAIT cells 180 
expressed low levels of CD69, with only a small TNF-a producing subpopulation and 181 
almost no IFN-g producing cells (Figure 1D).   182 
 183 
S. Typhimurium ST313 lineage 2 fails to elicit MAIT cell activation in healthy and 184 
susceptible individuals. 185 
 186 
To validate our unsupervised analysis, we infected PBMC with the different Salmonella 187 
strains at increasing multiplicity of infection (MOI), and then assessed MAIT cell 188 
activation by flow cytometry. Infection by STM-D23580 consistently induced limited 189 
MAIT cell responses across a range of MOIs and in every healthy donor tested. In 190 
comparison with STM-LT2, ST-Ty2 or E. coli, STM-D23580 stimulated MAIT cells 191 
significantly expressed less CD69 and produced less IFN-g and TNF-a (Figure 2A-D). 192 
This effect was not dependent on a selective loss of MAIT cells, as STM-D23580 did 193 
not have a detrimental effect on MAIT cell viability (SI Appendix, Figure S1A). gd T 194 
cells, a subset of innate T lymphocytes also present in PBMC, were strongly activated 195 
by STM-D23580, indicating that the lack of activation is a phenomenon limited to MAIT 196 
cells (Figure 2A, 2C).  197 
 198 
In culture, Salmonella spp. secrete vitamin B2 intermediates that can bind to MR1 on 199 
antigen presenting cells (APCs), to trigger MAIT cell activation [29]. To examine 200 
whether STM-D23580 secretes MAIT cell agonists, we collected supernatants from 201 
single-colony cultures to stimulate PBMC. Supernatants from STM-LT2 and E. coli 202 
induced a dose-dependent production of IFN-g and TNF-a by MAIT cells, whereas 203 
STM-D23580 supernatants did not (SI Appendix, Figure S1B).   204 
 205 
To validate such findings, we assessed MAIT cell responses to a broader selection of 206 
bacterial isolates, including two S. Typhi strains (ST-Ty2 and ST-Quailes) and one S. 207 
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Paratyphi A strain; in addition two differently sourced stocks of STM-D23580 were 208 
tested, to ensure that genuine sequence type 313 isolates were being used. At two 209 
different MOIs, STM-D23580 elicited the lowest levels of MAIT cell activation of the 210 
group (SI Appendix, Figure S1C-S1D). In contrast, gd T cell responses were 211 
comparable across all Salmonella pathovars (SI Appendix, Figure S1E-S1F).    212 
 213 
We next determined whether the lack of MAIT cell activation was caused by the entire 214 
S. Typhimurium ST313 clade or was a unique characteristic of ST313 lineage 2 which 215 
is currently causing most clinical disease in Africa [14]. STM-D23580 and additional 216 
isolates of ST313 lineage 2, were compared with closely-related isolates that were 217 
members of ST313 lineage 1 or the UK ST313 group that is associated with 218 
gastroenteritis (Figure 2E). To examine MR1-independent MAIT cell activation, we 219 
used Enterococcus faecalis as a negative control as it lacks the vitamin B2 biosynthetic 220 
pathway [29]. 221 
 222 
Remarkably, only the ST313 strains belonging to lineage 2, such as D23580, D37712 223 
and U60, failed to elicit MAIT cell activation (Figure 2F-2G). All other Salmonella ST313 224 
lineages tested (strains U2, U5 and D25248) triggered the same level of MAIT cell 225 
responses as S. Typhimurium 4/74 (STM-4/74) [40], a sequence type 19 strain that is 226 
closely related to STM-LT2 and is associated with non-invasive diarrhoeal infections.  227 
 228 
To validate our observations in a relevant population, we performed a series of assays 229 
on blood samples obtained from healthy adult residents of Malawi, an endemic area 230 
for iNTS infections caused by ST313 strains. We further expanded our investigation 231 
into the distinct ST313 clusters by infecting PBMC with four strains from lineage 1, four 232 
strains from lineage 2 and four strains from lineage 2.2. Lineage 2.2 comprises 233 
multidrug-resistant strains that differ from lineage 2 by 27 single nucleotide 234 
polymorphisms [41] and by 4 plasmids [42]. In comparison to the sequence type 19 235 
representative strain STM-4/74, PBMC infected with ST313 lineage 1 strains elicited 236 
similar MAIT cell responses, whereas infection with ST313 lineages 2 and 2.2 induced 237 
significantly lower levels of MAIT cell responses (Figure 3A and SI Appendix, Fig S2).  238 
 239 
Lastly, we extended our findings to a clinically susceptible cohort of HIV-infected adults 240 
living in Malawi. In comparison with a cohort of healthy samples from the UK and 241 
Malawi, and consistent with previous reports (reviewed in [43]), the overall percentage 242 
of MAIT cells was reduced among HIV-infected individuals, particularly in those not 243 
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receiving antiretroviral therapy (ART) (Figure 3B). In line with the data obtained with 244 
healthy volunteers, MAIT cells from HIV+ adults also failed to produce IFN-g and TNF-245 
a following ex vivo stimulation with STM-D23580, regardless of their ART status 246 
(Figure 3C). In contrast, MAIT cells from HIV+ individuals responded strongly to S. 247 
Typhi and STM-4/74.  248 
 249 
These findings suggest that evasion of MAIT cell recognition by sequence type 313 250 
Salmonella strains may be a critical factor during the course of natural iNTS disease 251 
in endemic populations and in clinically-susceptible groups. 252 
 253 
STM-D23580 does not affect MR1-dependent antigen presentation.   254 
  255 
To define the molecular mechanisms underlying the lack of MAIT stimulation by STM-256 
D23580, we first investigated whether MAIT cell activation was MR1-dependent. 257 
Adding the anti-MR1 blocking antibody 26.5 [44] completely abrogated the MAIT cell 258 
activation induced by STM-LT2 and E. coli, as well as the minimal activation induced 259 
by STM-D23580 (Figure 4A-4B).  260 
 261 
We next examined whether STM-D23580 either failed to produce stimulatory MR1 262 
ligands or actively inhibited MAIT cell activation. MAIT cell activation was restored 263 
following the addition of the canonical MAIT cell ligand 5-amino-6-D-ribitylaminouracil 264 
(5-A-RU) and methylglyoxal (MG) [33] to infected PBMC (Figure 4C-4D), 265 
demonstrating that a dominant antagonistic MR1 ligand was not released by STM-266 
D23580. Consistent with these results, a combination of supernatants from overnight 267 
cultures of both STM-D23580 and STM-LT2 (added simultaneously or one hour apart) 268 
fully restored MAIT cell activation (SI Appendix, Figure S3A-S3B). Likewise, co-269 
infection of PBMC with STM-D23580 plus either STM-LT2, ST-Ty2 or E. coli also 270 
restored MAIT cell activation to the levels observed with single infections (Figure 4E-271 
4F). Taken together, our data show that STM-D23580 neither interferes nor blocks 272 
MAIT cell activation in the presence of stimulatory MR1 ligands.  273 
 274 
To exclude the possibility that the lack of MAIT cell activation arose from an insufficient 275 
infection of APCs, we exposed Monocyte-derived Dendritic Cells (MoDCs) to 276 
fluorescently labelled STM-D23580 or STM-LT2. Live Salmonella-containing MoDCs 277 
were FACS-sorted and co-cultured with enriched autologous CD3+ T lymphocytes, as 278 
described previously [45]. In contrast to STM-LT2 infected MoDCs, STM-D23580 279 
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infected MoDCs did not stimulate effector MAIT cells (SI Appendix, Figure S3C). Using 280 
an MR1-overexpressing antigen presenting cell line, we found that STM-D23580 281 
supernatants do not cause downregulation of surface MR1 expression, thus excluding 282 
this as a possible cause of the lack of MAIT cell activation (SI Appendix, Figure S3D). 283 
 284 
Cytokines, such as IL-12, IL-18 and type I IFN, released by APCs upon bacterial or 285 
viral infection can also activate MAIT cells in a MR1-independent manner [31]. We 286 
confirmed that when MoDCs were co-cultured with purified MAIT cells, equal amounts 287 
of bioactive IL-12p70 were secreted upon infection with STM-D23580, STM-LT2 and 288 
E. coli (SI Appendix, Figure S3E). 289 
 290 
Taken together, these observations refuted the hypothesis that lack of MAIT cell 291 
activation is caused by an impaired MR1-dependent antigen-presentation following 292 
STM-D23580 infection. 293 
 294 
STM-D23580 evades MAIT cell recognition by overexpression of RibB.  295 
 296 
The observation that STM-D23580 and related ST313 isolates do not interfere with 297 
MR1 presentation or cytokine production suggests that these bacteria might not 298 
produce the MR1 binding ligands that are generated by other S. Typhimurium or S. 299 
Typhi pathovariants. The major source of natural antigens driving MAIT cell activation 300 
derives from by-products of microbial riboflavin synthesis [33]. We depict the 301 
Salmonella riboflavin biosynthetic pathway in Figure 5A. A comparison of the coding 302 
sequences (CDS) of the enzymes involved in the riboflavin biosynthesis pathway found 303 
only one nucleotide change (SNP) between the sequence type 19 STM-4/74 and the 304 
sequence type 313 STM-D23580 strains. This synonymous coding variant was located 305 
in the ribD gene (Glu316Glu) [46], suggesting that there were no biochemical 306 
differences between the riboflavin biosynthesis pathways of the sequence type 313 307 
and sequence type 19 isolates. 308 
 309 
To determine whether the enzymes of the riboflavin pathway of the sequence type 19 310 
STM-4/74 and sequence type 313 STM-D23580 strains were expressed at different 311 
levels, we investigated the transcriptomic and proteomic data from our recent 312 
comparative analysis [46]. Strains STM-4/74 and STM-D23580 are closely-related, 313 
sharing 92% of coding genes [46]. Differential gene expression analysis of the rib 314 
genes at the transcriptomic level identified significant up-regulation of ribB (>2 fold-315 
change, FDR <0.001) in STM-D23580 in four out of the five experimental conditions 316 
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(Figure 5B). We then examined data from a quantitative proteomic approach which 317 
showed that RibB protein levels were up-regulated in STM-D23580 compared to STM-318 
4/74, during growth in rich medium at early stationary phase (ESP) (Figure 5C).  319 
 320 
We searched for a molecular explanation for the high levels of ribB expression in STM-321 
D23580 compared to STM-4/74. In STM-D23580, ribB and its 5’ untranslated region 322 
(5’UTR) are transcribed as a single transcript that is initiated from a single gene 323 
promoter which we identified previously [46]. By analogy with the genetic mechanism 324 
identified for over-expression of the PgtE virulence factor in STM-D23580 [47] we 325 
searched for nucleotide polymorphisms that distinguished the ribB regions of the two 326 
strains. There were no differences between the promoter sequences of the ribB genes 327 
or the 5’ UTR of the strains STM-D23580 and STM-4/74.  328 
 329 
To determine whether the MAIT cell activation phenotype was linked to the 330 
overexpression of the RibB enzyme (4-dihydroxy-2-butanone 4-phosphate synthase), 331 
we created a derivative of STM-4/74 that expressed high levels of RibB. Since 332 
deletions in the riboflavin biosynthetic pathway genes are lethal without high dose 333 
riboflavin supplementation [33][48] and ribB is essential for Salmonella in vivo 334 
virulence [49], we used a gene cloning approach to overexpress the ribB gene of STM-335 
D23580 in STM-4/74 from a recombinant plasmid (STM-4/74 RibB++). The expression 336 
of high levels of the RibB enzyme by STM-4/74 ablated MAIT cell activation induced 337 
by wild-type STM-4/74. Infection with STM-4/74 RibB++ induced low levels of cytokine 338 
production and CD69 expression by MAIT cells, recapitulating the phenotype of STM-339 
D23580 (Figure 5D-5E). Importantly, gd T cells responded equally to both STM-4/74 340 
wild type and STM-4/74 RibB++ (SI Appendix, Figure S4). 341 
 342 
We next evaluated the bacterial growth rate, as well as the infection efficiency of the 343 
STM-4/74 RibB++ bacterial strain. Mid-log phase curves demonstrated no significant 344 
differences in the growth rate between STM-4/74 wild type, STM-4/74 RibB++ and other 345 
related strains (SI Appendix, Figure S5A). Human monocyte-derived dendritic cells 346 
and human monocyte-derived macrophages were infected in vitro, and the number of 347 
intracellular bacterial colony-forming units (cfu) was measured as a readout of 348 
internalisation. In both cell types tested, the number of recovered intracellular STM-349 
4/74 RibB++ was comparable to the number obtained from other Salmonella strains (SI 350 
Appendix, Figure S5B). These data exclude the possibility that the lack of MAIT 351 
activation by STM-4/74 RibB++ reflects slow growth or poor bacterial internalisation into 352 




MAIT activator ligands such as 5-OP-RU (5- (2-oxopropylideneamino)-6-D-355 
ribitylaminouracil) or 5-OE-RU (5- (2-oxoethylideneamino)-6-D-ribitylaminouracil), 356 
products of the riboflavin pathway, cannot be measured due to their unstable nature 357 
[33]. Therefore, to investigate whether overexpression of RibB altered the balance of 358 
downstream products from the riboflavin pathway, we measured the amount of 359 
riboflavin, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) by 360 
HPLC. Following growth to early stationary phase, intracellular samples and culture 361 
supernatants from STM-4/74 and STM-4/74 RibB++ contained larger amounts of 362 
riboflavin than the sequence type 313 strains STM-D23580 and STM-D37712 (Figure 363 
6A-6B). The STM-4/74 RibB++ supernatant with the highest level of riboflavin also 364 
contained the largest amount of FMN, compared with STM-4/74, STM-D23580 and 365 
STM-D37712 (Figure 6C).  366 
 367 
Overall, the data show that the RibB over-producing strain (4/74 RibB++) produced the 368 
highest level of extracellular riboflavin and FMN, whereas had the lowest level of 369 
intracellular FMN. In contrast, the STM-4/74 wild-type strain had the largest 370 
intracellular amount of FMN, compared with 4/74 RibB++ and both of the sequence type 371 
313 strains (Figure 6D). While intracellular FAD levels were similar between STM-4/74, 372 
STM-D23580 and STM-D37712, STM-4/74 RibB++ contained the lowest level of 373 
intracellular FAD (Figure 6E). We conclude that the lowest levels of intracellular FMN 374 
was found in the STM-D23580, STM-D37712 and STM-4/74 RibB++ strains that 375 
overexpress the RibB enzyme. 376 
 377 
Reduced MAIT cell antibacterial activity against S. Typhimurium ST313 lineage 378 
2 infected macrophages. 379 
 380 
To test the role of MAIT cells in clearing Salmonella infections, we developed an in 381 
vitro assay where human monocyte-derived macrophages were infected with the 382 
different Salmonella strains, either in presence or absence of purified MAIT cells. As 383 
observed with PBMC, we measured less IFN-g in supernatants from co-cultures of 384 
purified MAIT cells and macrophages infected with STM-4/74 RibB++ and sequence 385 
type 313 lineage 2 strains, as compared to the control sequence type 19 strains (SI 386 
Appendix, Figure S6A).  387 
 388 
In these experiments, the number of intracellular cfu recovered from infected 389 
macrophages was used as a surrogate of bactericidal activity induced by MAIT cells. 390 
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In the majority of the biological replicates and in comparison with macrophages alone, 391 
we observed a modest reduction of cfu numbers (25% or less) when MAIT cells and 392 
sequence type 313 lineage 2 infected macrophages were put in co-culture (SI 393 
Appendix, Figure S6B). In contrast, almost all biological replicates infected with 394 
sequence type 19 Salmonella had a reduction of more than 25% in the number of cfu 395 
when MAIT cells were added to the infected macrophages (SI Appendix, Figure S6B). 396 
No differences in bactericidal activity were observed between STM-4/74 RibB++ and 397 
STM-4/74. While macrophages pre-treated with IFN-g acquired bactericidal activity 398 
against all Salmonella isolates (SI Appendix, Figure S6C), MAIT cell anti-microbial 399 
activity in these in vitro co-cultures was not directly correlated to the amount of IFN-g 400 





Here we investigated the ability of MAIT cells to recognise and respond to diverse 404 
invasive Salmonella enterica serovars. We found that MAIT cells isolated from the 405 
blood of healthy individuals were not activated by exposure to invasive disease-406 
associated S. Typhimurium sequence type 313 (ST313) lineage 2 strains. Our data 407 
demonstrated how S. Typhimurium ST313 lineage 2 evades MAIT cell recognition by 408 
overexpressing ribB, a bacterial gene encoding the RibB enzyme involved in the 409 
riboflavin pathway. Our results lead us to propose that this RibB-mediated mechanism 410 
provides an evolutionary advantage that allows invasive S. Typhimurium ST313 411 
lineage 2 bacteria to escape cell immune responses by overexpressing a single 412 
riboflavin bacterial gene.  413 
 414 
MR1-restricted MAIT cells are highly abundant in the gut mucosa [50], where they 415 
reach their final maturation upon recognition of vitamin B2 metabolites derived from 416 
gut commensals presented by MR1 expressing mucosal B cells [50]. MAIT cells show 417 
antimicrobial activity in vivo and in vitro [51], [52] through MR1 dependent and 418 
independent interactions. Microorganisms must express the riboflavin biosynthesis 419 
pathway to be able to activate MAIT cells [29], [53]. Mutations in key enzymes of the 420 
riboflavin biosynthetic pathway in both Gram positive and negative bacteria can 421 
abrogate MAIT cell activation [33], [54]. Different bacteria that possess the riboflavin 422 
biosynthetic pathway induce varying levels of MAIT stimulation [36], [37], possibly 423 
through the influences of the microenvironment on bacterial metabolism and antigen 424 
availability, or the known short half-life of the potent MAIT cell antigens, 5-OP-RU and 425 
5-OE-RU [55]. The ability of MAIT cells to recognise and respond to several isolates 426 
of the same pathogen may also vary to reflect bacterial metabolic differences. For 427 
example, riboflavin metabolism variation among clinical isolates of Streptococcus 428 
pneumoniae produces different measurable levels of riboflavin and FMN that correlate 429 
with differential activation of MAIT cells [38].  430 
 431 
Salmonella spp. possess an active riboflavin biosynthetic pathway, which generates 432 
MAIT cell agonists [29], [33]. MAIT cells recognise and kill S. Typhimurium-infected 433 
targets in vitro [32], and activated MAIT cells accumulate in murine lungs following 434 
intranasal infection with S. Typhimurium [26]. However, bacterial lung clearance was 435 
independent of MAIT cells in this infection model, possibly due to the non-physiological 436 
route of infection. While some mouse models of infection with Salmonella sequence 437 
type 313 strains have been published [14], [56] , these models present limited utility as 438 
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mice have very low frequencies and absolute numbers of MAIT cells compared with 439 
humans [28]. Human studies demonstrated sustained MAIT cell activation and 440 
proliferation at the peak of infection with S. Typhi and S. Paratyphi [34], [35]. Among 441 
immunocompetent humans, the clinical outcomes of infection by Salmonella enterica 442 
spp. depend on the infecting serovar. Human-restricted typhoidal serovars, such as S. 443 
Typhi induce the most severe form of systemic disease, typhoid fever; while the broad-444 
host S. Typhimurium sequence type 19 causes self-limiting gastroenteritis. The 445 
recently documented multidrug resistant S. Typhimurium ST313 clade causes the 446 
majority of iNTS cases among immunocompromised adults and malnourished young 447 
children living in sub-Saharan Africa.  448 
 449 
Several bacterial factors have been reported to enhance invasiveness of S. 450 
Typhimurium ST313, suggesting a multifactorial adaptation of this African lineage to a 451 
systemic lifestyle. These include interference with the complement cascade [47], 452 
interference with DC function [45], reduced inflammasome activation [57], 453 
dissemination through CD11b+ migratory DC [58] among others.  454 
 455 
Here we found that S. Typhi, S. Paratyphi A and most S. Typhimurium pathovars 456 
potently elicited ex vivo MR1-dependent MAIT cell activation, but all tested isolates 457 
from the invasive S. Typhimurium ST313 lineage 2 barely induced cytokine secretion 458 
or CD69 upregulation. This suboptimal activation was restricted to MAIT cells, as gd 459 
cell activation was comparable across all isolates tested. We excluded differences in 460 
infection efficiency, MR1 expression, co-stimulatory cytokines (IL-12), the genetic 461 
sequence of the riboflavin encoding enzymes of S. Typhimurium and the presence of 462 
dominant inhibitory ligands as potential mechanisms for these results. Following 463 
comparative proteomic and transcriptomic analyses, we discovered that invasive S. 464 
Typhimurium ST313 lineage 2 pathovars escape MAIT cell recognition by 465 
overexpressing ribB, a bacterial gene encoding the riboflavin biosynthetic enzyme 466 
RibB. By overexpressing this single riboflavin gene in a sequence type 19 S. 467 
Typhimurium strain, we revealed that up-regulation of this single riboflavin gene was 468 
sufficient to abrogate MAIT cell responses.  469 
 470 
Transcriptional control of the bacterial ribB gene is controlled by a conserved FMN 471 
riboswitch, which is located in the 5′ untranslated region (5’ UTR) of ribB [59], and is 472 
negatively regulated by FMN and other flavins at the transcriptional and translational 473 
levels in E. coli [60]. The SroG small RNA (sRNA) is derived from the ribB 5’ leader 474 
sequence, although the function of this sRNA remains unknown [61]. In addition to the 475 
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riboswitch-mediated regulation, RibB expression is induced by growth in a low pH 476 
environment [62]. In STM-D23580, both sroG and ribB are transcribed as a single 477 
transcript that is initiated from a single gene promoter which we identified previously 478 
[46]. 479 
 480 
While the precise molecular mechanism responsible for ribB overexpression remains 481 
to be established, a single noncoding nucleotide polymorphism in the promoter of the 482 
pgtE gene of the ST313 lineage 2 strain STM-D23580 is known to be responsible for 483 
high expression of the outer membrane PgtE virulence factor, which promotes 484 
bacterial survival and dissemination during mammalian infection [47]. The lack of 485 
nucleotide differences between the promoter sequences of the ribB genes or the 486 
riboswitch of the two strains suggests that the high level of expression of ribB in STM-487 
D23580 is caused by a novel and uncharacterised regulatory mechanism. 488 
 489 
It has been proposed that genomic changes in ST313 isolates that confer altered 490 
metabolism and increased anaerobic metabolic capacity are linked to adaptation of the 491 
extra-intestinal niche [14]. Riboflavin and its derivatives are important cofactors for 492 
flavoproteins involved in cellular redox metabolism and several biochemical pathways, 493 
proposed to be essential for the metabolic adaptation of the ST313 clade. Riboflavin 494 
promotes intracellular microbial survival and virulence during in vivo infection with 495 
Histoplasma capsulatum and Brucella abortus [63], [64]. In addition, accumulation of 496 
riboflavin is a candidate virulence factor in Pseudogymnoascus destructans skin 497 
infection [65].  498 
 499 
The metabolomic measurements of the end-products of the riboflavin pathway showed 500 
a correlation between lower levels of intracellular FMN and increased expression of 501 
RibB. Because FMN is a negative regulator of ribB gene expression [60], we speculate 502 
that the lower levels of intracellular FMN observed in the ST313 strains D23580 and 503 
D37712 are linked to the high levels of expression of RibB in these African S. 504 
Typhimurium strains. 505 
 506 
Overall, our findings suggest that MAIT cells play a crucial role in defence against 507 
invasive Salmonella disease in humans and that evasion from MAIT cell recognition is 508 
a critical mechanism for the invasiveness of S. Typhimurium ST313 lineage 2 isolates, 509 
including those belonging to the lineage 2.2 cluster [41]. We propose that differences 510 
in MAIT cells activation may associate to distinct diseases caused by closely related 511 
microorganisms. The increased susceptibility of immunocompromised patients to the 512 
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S. Typhimurium ST313 lineage 2 strains suggests that MAIT cells might play a 513 
particularly relevant role in the context of waning CD4+ T cell mediated protective 514 
adaptive immunity, where protection relies mostly on the innate immune response. For 515 
example, following HIV co-infection and/or malnutrition, among individuals suffering 516 
from recurrent gut infections secondary to intestinal barrier dysfunction [66], [67], 517 
microbiota dysbiosis [68], [69] and multiple innate and adaptive immune defects [70]. 518 
Our findings may be of major relevance during the initial phase of infection, in the gut, 519 
where it is expected that resident immune cells such as MAIT cells should prevent 520 
systemic infection by encountering and responding rapidly to bacterial signals. We 521 
propose that the ability of MAIT cells to target gastrointestinal pathogens represents a 522 
key immunological evolutionary bottleneck that has been effectively countered by 523 
Salmonella, resulting in the current epidemic of invasive disease in Africa.  524 
 525 
 526 





Bacterial strains and preparation of stocks. 530 
This study included representative strains of Salmonella enterica serovar 531 
Typhimurium, from both the sequence type 19 and the sequence type 313. S. Typhi 532 
and S. Paratyphi A serovars were utilised as comparative Typhoidal invasive strains, 533 
while Escherichia coli (DH5α) was used as unrelated bacterial control. Supplementary 534 
Table 1 lists bacterial strains used in this study. 535 
Overnight bacterial cultures from a single colony origin were used to inoculate LB 536 
Lennox broth (Sigma) supplemented with sucrose (Sigma) at a final concentration of 537 
10%. Inoculated cultures were incubated at 37oC under constant shaking for 538 
approximately 3 hours, until reaching mid logarithmic phase. Bacterial aliquots were 539 
prepared and immediately frozen at -80oC for long-term storage. Bacterial viability of 540 
frozen aliquots was monitored periodically in order to maintain experimental 541 
reproducibility. The number of viable colony forming units (cfu) was determined with 542 
the Miles and Misra method, by plating 10-fold dilutions of the bacterial suspension 543 
onto LB Lennox agar (Sigma). On the day of the experiment, a single aliquot was 544 
thawed, washed twice with PBS and re-suspended in RPMI 1640 media to obtain the 545 
desired multiplicity of infection (MOI).  546 
In the case of bacterial supernatants, these were taken from late exponential phase 547 
cultures, grown from a single colony following 18 hours incubation under constant 548 
shaking. Supernatants were filter sterilised before using. 549 
 550 
Construction of S. Typhimurium 4/74 pPL-ribB 551 
To construct pPL-ribB, the ribB gene was amplified from genomic DNA of S. 552 
Typhimurium 4/74 using primers ribB_FW and ribB_RV. The PCR product was used 553 
for a linear amplification reaction with plasmid pJV300 (pPL) using Phusion DNA 554 
polymerase (New England Biolabs), and the resulting product was digested with DpnI. 555 
The plasmid was transformed into E. coli TOP10 and selected on LB plates 556 
supplemented with 100 μg/mL ampicillin. Plasmid presence was confirmed by PCR 557 
and DNA sequencing using oligonucleotides pPL_Seq_FW and pPL_Seq_RV. The 558 
pPL-ribB plasmid was subsequently purified and transformed into S. Typhimurium 559 
4/74. Supplementary Table 2 lists plasmids and oligonucleotides used in this study. 560 
 561 
Isolation of human cells from peripheral blood from healthy volunteers in the 562 
UK.  563 
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Leukocyte Reduction System cones were obtained from the UK National Blood Centre 564 
with informed consent following local ethical guidelines (NHSTB account T293). Blood 565 
was diluted in PBS and separated by gradient centrifugation using LymphoprepTM 566 
(AxisShield). Peripheral Blood Mononuclear Cells (PBMC) were collected from the 567 
interface, washed with PBS, resuspended in complete medium and counted. Complete 568 
medium used throughout was RPMI 1640 (Sigma), supplemented with 10% heat-569 
inactivated FCS (Sigma), 2 mM L-glutamine, 1% nonessential amino acids and 1% 570 
sodium pyruvate (all from Gibco). 571 
 572 
Isolation of PBMC from healthy and HIV-infected volunteers in Malawi.  573 
Blood samples were obtained at Queen Elizabeth Central Hospital (Blantyre, Malawi) 574 
following local ethical guidelines (P09/17/2284). Adults presenting for HIV testing at 575 
the voluntary testing clinic, the HIV outpatient clinic, and the medical inpatient wards 576 
at the Queen Elizabeth Central Hospital were recruited. Based on the use of 577 
antiretroviral therapy, these patients were classified as ART naïve (without) or ART 578 
treated (with). Upon appropriate consent and medical authorisation, a blood sample 579 
was collected and PBMC were isolated and used in ex vivo infection assays, as 580 
described below.  581 
 582 
Ex vivo infection assays with PBMC 583 
PBMC were seeded in 96 well plates round bottom (5 to 8 x105 cells per well) and 584 
infected with the different Salmonella strains from frozen mid-log phase stocks, at the 585 
indicated MOI. Upon 80 minutes incubation at 37oC, 100 µg/mL gentamicin (Lonza) 586 
was added to kill extracellular bacteria. 200 µg/mL of gentamicin was required for the 587 
experiments carried out in Malawi using ST313 strains from lineages 1, 2 and 2.2.  588 
At 180 minutes post-infection, 5ng/mL brefeldin A (BioLegend) solution was added to 589 
every well in order to achieve accumulation of intracellular cytokines. Samples were 590 
incubated overnight at 37oC for no more than 15 hours.   591 
For MR1 blocking experiments, infection was performed in the presence of 30 μg/mL 592 
MR1 blocking antibody 26.5 [44] or mouse IgG2a isotype control (ATCC). The MAIT 593 
agonists 5-Amino-6-D-ribitylaminouracil (5-A-RU) was synthesised as described [71] 594 
and 1 μg/mL was combined to 50 μM methylglyoxal (MG, Sigma). 595 
 596 
Assessment of cytokine production and MAIT cell activation by flow cytometry. 597 
Following incubation in the presence of brefeldin A, cells were harvested, washed and 598 
stained with a viability dye (live/dead Zombie Aqua, BioLegend) for 20 minutes. 599 
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Fixation was performed for 30 minutes at 4oC using the Foxp3 600 
Fixation/Permeabilization buffers (eBioscience). Fixed cells were permeabilised and 601 
stained with an antibody cocktail for 40 minutes at room temperature, washed and 602 
stored protected from light at 4oC in PBS with 0.5% bovine serum albumin (FACS 603 
buffer) until acquisition. The following antibodies were used for extracellular and 604 
intracellular staining as 2 different panels: anti-CD3 Alexa700 (clone UCHT1; 605 
BioLegend), anti-CD3 PerCp Cy5.5 (clone UCHT1; BioLegend), anti-CD4 APCef780 606 
(clone RPA-T4; eBioscience), anti-CD4 Alexa700 (clone RPA-T4; BioLegend), anti-607 
CD8 BV785 (clone RPA-T8; BioLegend), anti-TCR γ/δ APC (clone B1; BioLegend), 608 
anti-CD161 BV605 (clone HP-3G10; BioLegend), anti-CD161 BV421 (clone HP-3G10; 609 
BioLegend), anti-Vα7.2 PE (clone 3C10; BioLegend), anti-Vα7.2 PE-Cy7 (clone 3C10; 610 
BioLegend), anti-CD69 FITC (clone FN50; BioLegend), anti TNF- a PECy7 (clone 611 
Mab11; BioLegend), anti TNF- a APC (clone Mab11; BioLegend), anti-IFN- g FITC 612 
(clone 4S.B3; BioLegend) and anti-IFN- g PE Dazzle (clone 4S.B3; BioLegend). 613 
Samples from the UK were acquired on a FortessaX20 (BD), whilst samples from the 614 
case-control study in Malawi were acquired on a LSR Fortessa cytometer (BD). All 615 
data was analysed with the same gating strategy on FlowJo (v.10.6.1). 616 
 617 
Unsupervised analysis of flow cytometry data. 618 
Two dimensionality reduction methods based on a neighbouring graph approach were 619 
implemented, t-Distributed Stochastic Neighbour Embedding (t-SNE) [72] and Uniform 620 
Manifold Approximation and Projection (UMAP) [73]. t-SNE algorithm was performed 621 
on the Cytofkit platform [74] using up to 5,000 cells from each sample. UMAP was run 622 
as a plugin on FlowJo (v.10.4.1) using 15 nearest neighbours, a minimum distance of 623 
0.5 and Euclidean distance for selected parameters. Files with .fcs extension from 624 
related experimental conditions were concatenated before UMAP analysis.  625 
 626 
Co-culture of Salmonella infected monocyte-derived dendritic cells and purified 627 
T cells. 628 
Monocyte-derived dendritic cells (MoDCs) were obtained from PBMC by enrichment 629 
of CD14+ monocytes using magnetic beads (Miltenyi). Differentiation was achieved 630 
with recombinant human GM-CSF (40 ng/mL) and human IL-4 (40ng/mL), both from 631 
PeproTech. After 5 days, MoDCs were infected with violet-labelled (CellTracker™, Life 632 
Technologies) Salmonella strains, either STM-D23580 or STM-LT2 at an MOI of 10, 633 
as reported elsewhere [45].  634 
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At six hours post-infection, Salmonella-containing MoDCs were FACS sorted as single 635 
cells. Sorted MoDCs were co-cultured with magnetically enriched (Miltenyi) CD3+ T 636 
cells obtained from the same donor, at a ratio of 1 MoDC per 6 T cells. Following 12 637 
hours incubation in the presence of brefeldin A, T cells were harvested and stained for 638 
intracellular cytokines as described above. 639 
 640 
Co-culture of Salmonella infected MoDCs and expanded MAIT cells. 641 
Human MoDCs were obtained as described above. Human MAIT cells were isolated 642 
by sorting CD2 MACS-enriched (Miltenyi) leukocytes with CD161 and Vα7.2 643 
antibodies (BioLegend). MAIT cells were grown for around 6 weeks in complete RPMI 644 
media supplemented with IL-2, as described elsewhere [71]. 645 
40,000 MoDCs and 20,000 MAIT cells (2:1 ratio) were seeded in 96 well plates flat 646 
bottom and were infected at MOI of 3.5. After 80 minutes, 100 μg/mL gentamicin was 647 
added and supernatants were harvested following 26 hours incubation. IL-12 p70 was 648 
measured by ELISA (R&D systems) in triplicates and following manufacturer’s 649 
instructions. 650 
 651 
Co-culture of Salmonella infected monocyte-derived macrophages and 652 
expanded MAIT cells. 653 
Monocytes were obtained from leukocyte reduction system cones by enrichment of 654 
CD14+ cells using magnetic beads (Miltenyi), according to manufacturer’s protocol. 655 
Monocytes were seeded in 24-well plates (450,000 - 500,000 cells/well) and 656 
differentiated into macrophages using recombinant human M-CSF at 100 ng/mL 657 
(PeproTech). After 6 days of incubation at 37oC and 5% CO2, the adherent 658 
macrophages were carefully washed to remove M-CSF containing-media and fresh 659 
antibiotic-free medium was added. Next, macrophages were infected with the different 660 
Salmonella strains at a MOI of 15. After 30 minutes post-infection, cells were washed 661 
and incubated for further 30 minutes with 100 µg/mL of gentamicin-containing medium 662 
to kill any remaining extracellular bacteria. At 1 hour post-infection, macrophages were 663 
washed again and MAIT cells were added (ratio 1 MAIT cell per 5 macrophages) into 664 
the respective wells. From this point and onwards, media contained gentamicin at 30 665 
µg/mL as maintenance dose. Cells were incubated until completing 6 hours post-666 
infection before being washed twice with PBS and lysed with 2% saponin. The number 667 
of intracellular viable bacterial cfu was determined with the Miles and Misra method as 668 
described above. IFN-g in the supernatants was measured with a commercial ELISA 669 




MR1 over-expressing cell line 672 
THP-1 cells were transduced with an MR1 encoding lentivirus [34]. MR1 673 
overexpressing cells were seeded in 96 well plates flat bottom and incubated overnight 674 
in the presence of 50 μL of supernatants from bacterial cultures at late exponential 675 
phase, or in the presence of 5-A-RU as positive control. Cells were harvested, washed 676 
and stained for surface expression of MR1 (clone 26.5; BioLegend) by flow cytometry. 677 
Expression of MHC-I (clone G46-2.6, BD Biosciences) was also monitored as 678 
unrelated control.  679 
 680 
Transcriptomic and proteomic analyses of riboflavin enzymes. 681 
RNA-seq and proteomic data for genes involved in the riboflavin biosynthetic pathway 682 
were extracted from a recent work [46]. Briefly, a differential expression comparative 683 
analysis between strains STM-D23580 and STM-4/74 was performed at the 684 
transcriptomic level in five in vitro infection-relevant conditions: ESP (early stationary 685 
phase), anaerobic growth, NonSPI2 (SPI2-non-inducing PCN), InSPI2 (SPI2-inducing 686 
PCN) and inside murine RAW264.7 macrophages (ATCC TIB-71). Specific details 687 
about growing bacteria in these conditions had been previously described [40], [75]. 688 
For a comparative proteomic analysis, bacteria were grown to ESP in the LB rich 689 
medium. 690 
The RNA-seq-based comparative approach between STM-D23580 and STM-4/74 was 691 
based on Voom/Limma analysis from three different biological replicates for each 692 
strain. A detailed pipeline for the analysis can be found in Canals et.al. [46]. 693 
Proteomic data for strains STM-D23580 and STM-4/74 were obtained using an LC-694 
MS/MS (Q Exactive Orbitrap, 4h reversed phase C18 gradient) platform. Samples 695 
included six biological replicates for each strain. Label-free quantification and 696 
differential expression analyses between the two strains were performed using the 697 
Progenesis QI software (Nonlinear Dynamics) [46]. 698 
 699 
Measurement of riboflavin, FMN and FAD in supernatants and pellets of bacterial 700 
cultures. 701 
Bacterial pellets and supernatants from early stationary phase cultures (OD600=~2), 702 
were prepared in triplicate and frozen at -80 oC. For extraction of cellular flavins, pellets 703 
were resuspended in 100 μL of 100 mM ammonium formate, 100 mM formic acid, 25% 704 
(v/v) methanol and heated at 80 oC for 10 min. Insoluble material was removed by 705 
centrifugation. For analysis 5 μL of this material or the culture supernatants was 706 
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separated by HPLC on a Dionex UPLC system with a Kinetex C18 column 707 
(Phenomenex; 1.7 um, 150 x 2.1 mm). Separation was achieved at 45 oC and 0.2 708 
mL/min isocractically using 20 mM potassium phosphate buffer (pH 2.5) with 25% 709 
methanol (v/v) over 8 min followed by a 1 min wash step in 100% methanol. Flavins 710 
were detected with fluorescence (450 nm excitation, 520 nm emission) and peaks were 711 
quantified by comparison to known standards. For normalisation the total pmol of flavin 712 
for each culture was divided by the measured OD600 of the cultures to give a final 713 
pmol/OD600 value. 714 
 715 
Statistical analysis 716 
Statistical analyses were performed using GraphPad-Prism8 (GraphPad Software; 717 
San Diego, United States). Differences among groups were determined by paired one-718 
way, two-way ANOVA or Kruskal-Wallis as appropriate. Post-hoc corrections were 719 
applied, Dunnett’s or Dunn’s for comparisons to a control data set and Bonferroni’s, 720 
Tukey’s or Sidak’s for comparisons of selected pairs tests, as appropriate. A p-value 721 
<0.05 was considered statistically significant (*p <0.05, **p <0.01, ***p <0.001 and 722 
****p <0.0001). 723 
 724 
Data Availability 725 





FIGURE LEGENDS 729 
 730 
Figure 1. Identification of cellular responses to multiple Salmonella enterica 731 
subsp enterica serovars.  732 
PBMC were left unstimulated or were infected at MOI of 5 with STM-D23580, STM-733 
LT2, ST-Ty2 or E. coli. Intracellular staining was performed to detect CD69 expression 734 
and cytokine production (TNF-a and IFN-g), as correlates of T cell activation. (A) t-735 
SNE plots on gated CD69+ CD3+ T cells infected with STM-D23580, STM-LT2, ST-Ty2 736 
or E. coli. Four CD3+ T cell populations (CD4+, CD8+, gd+ and MAIT) were annotated 737 
based on the expression of distinct phenotypic markers. CD4, CD8, TCRgd, Va7.2+, 738 
CD161, IFN-g and TNF-a were the parameters included for t-SNE analysis. Plots 739 
correspond to one representative donor. (B) t-SNE plots as in (A) showing relative 740 
expression of TNF-a and IFN-g on CD69+ CD3+ T cells. (C) UMAP analysis on 741 
concatenated CD3+ Va7.2+ CD161+ MAIT cells from the same donor as in (A) and (B). 742 
Calculated UMAPs are shown for each experimental condition. CD69, IFN-g and TNF-743 
a were the parameters included for analysis. (D) Top left panel showing UMAP as an 744 
overlay of concatenated MAIT cell populations from (C): unstimulated in light grey, 745 
STM-D23580 in blue, STM-LT2 in green, ST-Ty2 in red and E. coli in dark grey. Top 746 
right and bottom panels: UMAPs showing expression of CD69, TNF-a and IFN-g in 747 
pink. (A-D) Data from one donor representative of four biological replicates. 748 
 749 
Figure 2. S. Typhimurium ST313 lineage 2 fails to elicit MAIT cell activation. 750 
PBMC were left unstimulated (U) or were infected with a variety of Salmonella strains 751 
at the indicated MOI. E coli was included as positive control and E. faecalis as negative 752 
control. (A) Production of TNF-a and IFN-g by MAIT and gd+ T cells was detected by 753 
intracellular staining. Representative flow cytometry plots from one volunteer are 754 
shown. (B) Percentage of TNF-a and/or IFN-g producing MAIT cells when stimulated 755 
at increasing MOI, from 0.5 to 20 bacteria per cell. Data represented as mean + SEM, 756 
two-way ANOVA + Dunnet’s, n=4. (C) CD69 staining profile of stimulated MAIT and 757 
gd+ T cells. Representative histograms from one volunteer are shown. (D) CD69 758 
expression on MAIT cells when stimulated as in (B). Data represented as geometric 759 
mean + SEM, two-way ANOVA + Dunnet’s, n=4. (E) Phylogenetic relationships 760 
between strains used in these experiments (red) within the context of Salmonella 761 
enterica phylogeny. (F) Percentage of TNF-a and/or IFN-g producing MAIT cells, 762 
treated with bacterial strains at MOI of 2.5 and 5. Data represented as mean + SEM, 763 
two-way ANOVA + Dunnet’s, n=4. (G) Levels of CD69 expression on MAIT cells 764 
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treated as in (E). Data represented as geometric mean + SEM, two-way ANOVA + 765 
Dunnet’s, n=4. 766 
 767 
Figure 3. Characterisation of MAIT cell responses to Salmonella spp. in relevant 768 
and susceptible cohorts of individuals. 769 
(A) PBMC were isolated from ten healthy individuals living in Malawi. Cells were 770 
infected at MOI of 7 with various strains from sequence type 313 (ST313) lineages 1, 771 
2 and 2.2 or with the sequence type 19 (ST19) reference strain STM-4/74. Each dot 772 
represents the average of TNF-a and/or IFN-g producing MAIT cells per individual 773 
upon stimulation with 4 strains from each lineage (see Figure S2). Median + IQR, 774 
Friedman + Dunn’s, n=10 for each group. (B) Percentage of MAIT cells (CD3+ Va7.2+ 775 
CD161+) in PBMC isolated from healthy (n=12) and HIV-infected individuals living in 776 
Malawi, with (n=6) or without ART (n=6). Data represented as percentage of live CD3+ 777 
T cells, median with IQR, Kruskal-Wallis + Dunn’s. (C) PBMC isolated from HIV+ 778 
patients with or without ART were infected at MOI of 7 with either STM-D23580, STM-779 
4/74, STy-H58 or E. coli. PMA/ionomycin was used as positive control. Data 780 
represented as percentage of TNF-a and/or IFN-g producing MAIT cells, mean + SEM, 781 
one-way ANOVA + Dunnet’s, n=6 for each group. 782 
 783 
Figure 4. STM-D23580 does not affect MR1-dependent antigen presentation.  784 
(A) PBMC were infected (at MOI 2.5 and 7.5) with STM-D23580 (blue), STM-LT2 785 
(green) or E. coli (grey), and incubated in the presence of anti-MR1 blocking antibody 786 
or the equivalent isotype control. Data are represented as percentage of TNF-a and/or 787 
IFN-g producing MAIT cells, box-and-whisker plot, two-way ANOVA + Dunnet’s, n=4. 788 
(B) Representative example of cytokine production by stimulated MAIT cells treated 789 
as in (A). (C- D) PBMC were left unstimulated or were infected (at MOI 2.5 and 5) with 790 
either STM-D23580 or STM-LT2, in the presence (pink bars) or absence (grey bars) 791 
of the MR1 ligands 5-A-RU and MG. Percentage of cytokine producing MAIT cells and 792 
their CD69 expression are shown. Data represented as mean and geometric mean + 793 
SEM, two-way ANOVA + Bonferroni’s, n=4. (E) PBMC were infected with D23580 at 794 
MOI of 2.5, alone or in combination with STM-LT2 (green), ST-Ty2 (orange) or E. coli 795 
(grey), at two different MOI (2.5 and 5). Data represented as percentage of TNF-a 796 
and/or IFN-g producing MAIT cells, mean + SEM, one-way ANOVA + Sidak’s, n=5. (F) 797 





Figure 5.  STM-D23580 evades MAIT cell recognition by overexpression of ribB. 801 
(A) Schematic representation of Salmonella’s riboflavin pathway, adapted from 802 
Soudais et al. [54]. (B) The relative transcriptional expression levels of the ribABDEFH 803 
genes were derived from our published RNA-seq data set [46]. The gene expression 804 
values from STM-D23580 and STM-4/74 were determined in five infection-relevant 805 
conditions: ESP (early stationary phase), anaerobic growth, NonSPI2 (SPI2-non-806 
inducing PCN), InSPI2 (SPI2-inducing PCN), and macrophage (intra-RAW264.7 807 
murine macrophage environment). Values indicate fold-change (FC) and false 808 
discovery rate (FDR), calculated from a Voom/Limma analysis (using Degust) for the 809 
RNA-seq data comparison of STM-D23580 versus STM-4/74. Data represent three 810 
biological replicates. PCN = phosphate carbon nitrogen minimal medium. (C) The 811 
relative expression levels of the RibABDEFH proteins were derived from our published 812 
proteomic data set for the ESP condition [46]. The heat map shows differential 813 
expression analysis following comparison between STM-D23580 and STM-4/74. 814 
Results from LC-MS/MS were analysed using the Progenesis QI software (Nonlinear 815 
Dynamics) for label-free quantification analysis. Each sample represents six biological 816 
replicates. Data represented in panels B and C were extracted from Canals et.al. [46]. 817 
(D) PBMC were infected at two different MOI (2 and 5) with STM-D23580 (blue), STM-818 
4/74 (green) or STM-4/74 RibB++ (pink). Data represented as percentage of TNF-a 819 
and/or IFN-g producing MAIT cells, mean + SEM, two-way ANOVA + Tukey’s, n=6. (E) 820 
CD69 staining profile of stimulated MAIT cells treated as in (D). Representative 821 
histograms from one volunteer are shown, MFI=Median Fluorescence Intensity. 822 
 823 
Figure 6. STM-4/74 RibB++ has the lowest intracellular levels of FMN, a negative 824 
regulator of ribB gene expression. 825 
Supernatants from early stationary phase and bacterial pellets were harvested and 826 
analysed by HLPC using riboflavin, FMN and FAD standards. Data is reported in pmol 827 
and has been normalised to the absorbance (OD600) from each culture. (A) Riboflavin 828 
levels in supernatants. (B) Intracellular riboflavin levels. (C) FMN levels in 829 
supernatants. (D) Intracellular FMN levels. (D) Intracellular FAD levels. Measurements 830 
were obtained from 3 biological replicates, mean + SEM, one-way ANOVA + Dunnet’s.   831 
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